Form 8-K JOHNSON & JOHNSON For: Oct 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Johnson & Johnson (JNJ) PT Raised to $181 at RBC Capital
October 16, 2024 6:50 AM EDTRBC Capital analyst Shagun Singh raised the price target on Johnson & Johnson (NYSE: JNJ) to $181.00 (from $178.00) while maintaining a Outperform rating.
The analyst comments "JNJ delivered a Q3 beat on sales/EPS that sent the stock up ~2% today. The company delivered +5.6% y/y underlying... More
Johnson & Johnson (JNJ) PT Raised to $170 at Stifel
October 15, 2024 2:22 PM EDTStifel analyst Rick Wise raised the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $160.00) while maintaining a Hold rating.
The analyst comments "Helped by better-than-expected 3Q24 Pharmaceutical division performance, both JNJ 3Q24 sales and EPS outperformed Stifel and consensus. And looking ahead, the company's... More
Citi Reiterates Buy Rating on Johnson & Johnson (JNJ)
October 15, 2024 8:20 AM EDTCiti analyst Joanna Wuensch reiterated a Buy rating and $180.00 price target on Johnson & Johnson (NYSE: JNJ).
The analyst comments "JNJ delivered 3Q24 revenue of $22.5B (up 5.6% organic) ahead of consensuss $22.2B. Innovative Medicine sales were $14.58B (up 6.7% organic ex-Covid-19, versus consensuss... More

